ent-Abacavir EP Impurity D
✓
100 % Datengenauigkeit
Wissenschaftlicher Support rund um die Uhr
⬡
0 % Toleranz bei der Produktqualität

Lagerstandorte

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

2079853-44-2ent-Abacavir EP Impurity D

● Auf Lager

Katalog-Nr.::VE0025011
CAS-Nr.::2079853-44-2
Summenformel::C14H18N6O
Molare Masse::286.34 g/mol

Zusätzliche Informationen zu CAS 2079853-44-2

Parent drug

Abacavir

IUPAC-Name

((1S, 4S)-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)cyclopent-2-en-1-yl)methanol

Pharmakopöe-Synonyme

N/A

Other Synonyms

N/A

SMILES

OC[C@@H]1C=C[C@@H](N2C=NC3=C(NC4CC4)N=C(N)N=C23)C1

InChI

InChI=1S/C14H18N6O/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21/h1, 4, 7-10, 21H, 2-3, 5-6H2, (H3, 15, 17, 18, 19)/t8-, 10-/m1/s1

Beschreibung

ent-Abacavir EP Impurity D (CAS 2079853-44-2) is a stereochemical impurity encountered during synthesis and storage of abacavir. Analytical characterization typically employs chiral HPLC and LC-MS with confirmatory NMR to define retention behavior | mass fragments and stereochemical configuration. This low-level enantiomeric impurity can arise from epimerization or incomplete stereoselective synthesis and has implications for potency | stability and regulatory compliance. Robust impurity profiling | validated chiral analytical methods | targeted degradation studies and tight specification limits are recommended to monitor and control its presence in drug substance and formulation. Data-driven risk assessment supports appropriate acceptance criteria and mitigation strategies.

Angebot anfordern

„*“ zeigt erforderliche Felder an

Dieses Feld dient zur Validierung und sollte nicht verändert werden.
Products quotation
Name
Url